Palexia (Tapentadol Hydrochloride)

Tapentadol hydrochloride, the active ingredient in Palexia, is an opioid analgesic presented as a strength/form for oral use. It is indicated for the management of moderate to severe acute pain in adult patients when alternative treatments are inadequate. GNH USA supplies Palexia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Palexia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Palexia (tapentadol) is an opioid analgesic that acts on the central nervous system to relieve pain. It is used in the following clinical situations:

- Acute postoperative pain: Provides effective analgesia after surgical procedures. - Chronic musculoskeletal pain: Helps manage persistent pain from conditions such as osteoarthritis. - Cancer‑related pain: Used as part of a multimodal regimen for moderate to severe cancer pain. - Neuropathic pain associated with diabetic peripheral neuropathy: Reduces pain intensity.

Tapentadol may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Nausea and vomiting - Constipation - Dizziness - Headache - Somnolence - Dry mouth

Serious or Rare Side Effects: - Respiratory depression - Seizures - Severe hypotension - Allergic reactions such as anaphylaxis - Serotonin syndrome - Adrenal cortisol suppression

When using Palexia, several safety considerations should be observed:

- Assess patient risk for opioid abuse: Conduct screen and monitor use through regular assessment. - Adjust dose in renal impairment: Use caution and consider lower doses. - Adjust dose for hepatic function and elder ‑ t t   a 

-   t  t """""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""